Phlow Corp. just dropped a $37 million Series C, and no, this isn’t your typical “another day, another round” pharma headline. This is a chemical-level shift in how America defends its drug supply, built not in some offshore lab, but right in Richmond, Virginia, where the molecules mean business. Align Private Capital led the round, joined by a mix of new and returning believers. That’s over $93 million in private backing, plus more than $600 million in government contracts. When your private and public books both look like this? You’re not raising capital, you’re raising eyebrows.
This isn’t just about capacity. It’s about capability. Co-founders Dr. Eric S. Edwards and Dr. B. Frank Gupton didn’t walk in with a pitch deck and a dream. They walked in with a track record that reads like a masterclass in pharmaceutical engineering. Edwards brought the AUVI-Q epinephrine injector to market at Kaleo Inc. and holds enough degrees from Virginia Commonwealth University to start his own Ivy League. Gupton, meanwhile, is a 30-year industrial chemist and VCU’s Floyd D. Gottwald Chair of Pharmaceutical Engineering. These two didn’t just co-found Phlow Corp., they architected a response to decades of American dependence on unstable, foreign supply chains.
Phlow Corp. is now running kilo-scale and metric-ton-scale cGMP manufacturing in Petersburg, Virginia. That’s 60 metric tons of API annually, backed by continuous flow chemistry, AI-powered execution systems, and a quality infrastructure that would make even Swiss regulators nod. They’re moving from ingredients to finished dosage forms, with fill-finish coming down the line. And yes, they’ve already delivered 1.6 million doses to the U.S. Strategic National Stockpile. When the country needed sedatives and antibiotics during the pandemic, Phlow Corp. didn’t blink, they scaled.
The new cash will fuel their “cdmoX” program, which is Phlow Corp.’s way of saying: we’ll build your pharma backbone with science that moves faster, cleaner, and smarter. With partnerships like Civica Rx, VCU’s Medicines for All Institute, AMPAC Fine Chemicals, and U.S. Pharmacopeia, this isn’t a solo act. It’s a coordinated strike against the status quo.
CFO Dave Ryan, President Dan Hackman, and the advisory muscle behind names like Melinda Hancock and Martin VanTrieste are laying down the commercial track while the tech runs at full tilt. AI meets GMP. Speed meets trust. Innovation meets execution.
